Aptevo (APVO) Director Zsolt Harsanyi Receives 400 Shares

What Happened

• Zsolt Harsanyi, a director of Aptevo Therapeutics (APVO), had 400 restricted stock units (RSUs) convert into 400 shares of common stock on August 6, 2026. The Form 4 shows 400 shares acquired via conversion (derivative code M) and 400 shares disposed at $0.00 (also coded as M).
• The conversion price is listed as N/A for the acquisition and $0.00 for the disposition; total cash value shown for the disposition is $0. The filing’s footnotes explain RSUs convert one-for-one into common stock and that the RSUs were originally granted on August 6, 2025 and vested on their first anniversary.

Key Details

• Transaction date: August 6, 2026.
• Acquisition: 400 shares via conversion of RSUs (derivative code M); price N/A.
• Disposition: 400 shares at $0.00 (derivative code M); reported value $0.00.
• Footnote F1: RSUs convert one-for-one into common stock.
• Footnote F2: 7,200 RSUs (400 post-split) were granted on 2025-08-06 and vested on the first anniversary.
• Shares owned after the transaction: not specified in the provided excerpt of the filing.
• Filing date: August 10, 2026 (filed four days after the transaction); Form 4s are generally due within two business days, so this may be late—see the official filing for any timeliness notation.

Context

• This was a conversion of RSU awards rather than an open-market buy or sale. The 400-share disposition at $0.00 typically reflects shares withheld or surrendered to satisfy tax or withholding obligations upon vesting/conversion; the filing does not show a market sale for cash.
• Such conversions/withholdings are routine for vested awards and do not necessarily indicate a change in the insider’s market view.